SEC Company Response from ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Sep 16, 2014
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Sept. 16, 2014 · CIK: 0001612940 · Accession: 0001193125-14-342306
AI Filing Summary & Sentiment
File numbers found in text: 333-198151
Letter
September 16, 2014
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler
Bryan J. Pitko
Re: ProQR Therapeutics B.V.
Registration Statement on Form F-1
File No. 333-198151
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective underwriters of the above issue, hereby join in the request of ProQR Therapeutics B.V. that the effectiveness of the Registration Statement on Form F-1 (Registration No. 333-198151) be accelerated so that the Registration Statement will become effective at 4:00 P.M. Eastern Time on September 17, 2014, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that the underwriters have effected between September 8, 2014 and the date hereof approximately the following distribution of the preliminary prospectus:
818 to institutions;
200 to prospective underwriters; and
226 to others.
The undersigned, as the representatives of the prospective underwriters of the above issue, hereby represent on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
[Remainder of Page Intentionally Left Blank; Signature Page Follows]
Very truly yours,
LEERINK PARTNERS LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP September 16, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler Bryan J. Pitko Re: ProQR Therapeutics B.V. Registration Statement on Form F-1 File No. 333-198151 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective underwriters of the above issue, hereby join in the request of ProQR Therapeutics B.V. that the effectiveness of the Registration Statement on Form F-1 (Registration No. 333-198151) be accelerated so that the Registration Statement will become effective at 4:00 P.M. Eastern Time on September 17, 2014, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that the underwriters have effected between September 8, 2014 and the date hereof approximately the following distribution of the preliminary prospectus: 818 to institutions; 200 to prospective underwriters; and 226 to others. The undersigned, as the representatives of the prospective underwriters of the above issue, hereby represent on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering. [Remainder of Page Intentionally Left Blank; Signature Page Follows] Very truly yours, LEERINK PARTNERS LLC DEUTSCHE BANK SECURITIES INC. LEERINK PARTNERS LLC By: /s/ Jon Civitarese Name: Title: Jon Civitarese Managing Director DEUTSCHE BANK SECURITIES INC. By: /s/ Benjamin Marsh Name: Title: Benjamin Marsh Director By: /s/ John Reed Name: Title: John Reed Director